CD14 and melanoma: A recent work by Krieg et al. showed, however, that the circulating counterpart of classical monocytes (CD14+CD16-HLA-DR+) actually seem to be associated with better response in melanoma patients undergoing anti-PD-1 therapy (16), which is in contrast to our findings.